Comprehensive patent landscape analysis for US Patent 10,293,030: lyophilized unpegylated interferon beta‑1a formulation claims, scope, and US generic risk
US Patent 10,293,030 is directed to a specific lyophilized pharmaceutical formulation of unpegylated recombinant interferon beta‑1a with defined amounts of trehalose (and optional sucrose), a defined class of non-ionic surfactant (polysorbate or polyethylene glycol), defined pH and buffer/antioxidant components, plus downstream claims to the reconstituted aqueous composition, IV use, and delivery device/siliconized container.
The claim set is broad at the ingredient-class level (surfactant class, buffering agent species combinations, antioxidant optionality) but narrow at the formulation-property level (trehalose dihydrate presence and ranges, surfactant concentration ranges, residual moisture cap, pH window post-reconstitution, interferon beta‑1a potency threshold). The most litigation-relevant elements for US generic entry are (i) whether an accused product is “lyophilised,” (ii) whether it uses unpegylated interferon beta‑1a with the claimed potency threshold, (iii) whether it meets the trehalose dihydrate (or trehalose+dihydrate+sucrose mix) requirement and the specific mass range per single dose, (iv) whether the surfactant falls within polysorbate or polyethylene glycol and within the claimed range, and (v) whether it satisfies the residual moisture and reconstitution pH windows. Delivery-device claims add an additional infringement pathway, but in practice are often harder for ANDA filers to design around without changing containerization.
What does US 10,293,030 claim, and what parts are most infringement-sensitive?
Key infringement hinges (independent claim 1):
- Lyophilized dosage form
- Unpegylated recombinant interferon beta‑1a (single-dose amount 2.0–15 μg)
- Bulking agent is disaccharide trehalose dihydrate or trehalose dihydrate mixed with sucrose, 30–50 mg per single dose
- Non-ionic surfactant is selected from polysorbate or polyethylene glycol
- Interferon beta‑1a potency is “biological activity higher than 150 MIU/mg”
These elements define the “core” right. Dependent claims further narrow with buffering species, antioxidants (methionine), residual moisture %, specific aqueous preparation, specific IV administration and disease indications, and container/siliconization.
Claim-by-claim scope summary
Claim 1 (independent): lyophilized interferon beta‑1a + trehalose + non-ionic surfactant + potency + dose ranges
- Trehalose requirement is central: trehalose dihydrate (or trehalose dihydrate+sucrose mix) in 30–50 mg per dose.
- Surfactant is constrained by class (polysorbate or polyethylene glycol), but not by individual polysorbate number (e.g., polysorbate 20 vs 80) based on the text you provided.
- Interferon β‑1a potency threshold is explicit (“>150 MIU/mg”), which can become a measurable proof point in both validity and infringement (assays, lot-to-lot variation, and labelable potency standards).
- Residual moisture is not in claim 1 but appears in claim 9 (dependent).
Claims 2, 5 (buffering and pH after reconstitution)
- Reconstituted pH window: about 5.5 to 7.5.
- Buffer species in claim 5: disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate, trisodium citrate dihydrate, or combinations.
Claims 6–7 (antioxidant)
- Antioxidant optional in claim 6, then methionine specifically in claim 7.
- This matters because methionine presence can be a design-around lever (removing methionine) if that does not alter stability or meet performance specs required by claim 6/7. Still, claim 1 does not require antioxidant.
Claims 3–4 (trehalose only / polysorbate-specific)
- Claim 3 fixes trehalose dihydrate only (no sucrose).
- Claim 4 fixes polysorbate specifically and trehalose dihydrate.
Claims 8, 11–13 (recombinant identity; aqueous formulation blueprint; concentration ranges)
- Claim 8 narrows to recombinant human interferon beta‑1a.
- Claim 11 recites a preparation-from aqueous solution pH 5.5–7.5 with components (i) interferon β‑1a, (ii) trehalose dihydrate or trehalose+sucrose mix, (iii) polysorbate or polyethylene glycol, (iv) buffer combination of disodium phosphate dihydrate/sodium dihydrogen phosphate dihydrate/trisodium citrate dihydrate, (v) methionine.
- Claim 12 constrains aqueous composition concentrations: 0.05–0.15% (w/v) polysorbate or polyethylene glycol and 2–6% (w/v) trehalose dihydrate or mixture.
- Claim 13 fixes polysorbate in the aqueous solution.
Claims 9–10 (residual moisture content)
- Moisture cap: not more than 5% by weight.
- Dependent refinement: 1–5%.
Claims 14–19 (reconstituted aqueous composition, IV administration, delivery device, prefilled syringe, siliconized inner surface)
- Claim 14 is an aqueous pharmaceutical composition obtained by reconstituting the lyophilized formulation.
- Claim 15 limits to IV administration.
- Claim 16–19 add delivery-device/prefilled-syringe packaging with siliconized inner surfaces.
Claims 20–23 (methods of treatment and administration)
- Claim 20 is treatment method using the lyophilized formulation for specified inflammatory/vascular conditions (ARDS vascular leakage/SIRS, ischemia-reperfusion injury in vascular/cardiac surgery and transplant contexts, ischemic pre-conditioning, MOF).
- Claims 22–23 apply to aqueous reconstituted composition IV administration with same indication set.
Most infringement-sensitive dependent claims for design-around
| Element |
Appears in |
Why it matters in infringement |
| Residual moisture ≤5 wt% (and 1–5 wt%) |
Claims 9–10 |
Many lyophilized products can meet moisture specs; but if an accused product targets higher moisture or uses different drying endpoints, it can reduce risk. Conversely, meeting the cap increases risk. |
| Post-reconstitution pH about 5.5–7.5 |
Claim 2 (and claim 11) |
pH is typically controlled by buffer system. If an accused product uses a different buffer system or aims outside this window, it can avoid. |
| Specific buffer species (phosphate dihydrate forms + citrate) |
Claim 5 (and claim 11) |
Limits species; a product using alternative buffers (e.g., histidine, acetate, succinate) could fall outside. |
| Methionine antioxidant |
Claims 6–7 (and claim 11) |
If methionine is present, dependent claims are easier to map. Removing methionine might avoid these dependent claims, though it does not avoid claim 1. |
| Aqueous composition concentration ranges |
Claims 11–13 (notably claim 12) |
A candidate product must map not only to final lyophilized composition but also to aqueous precursor ranges, depending on how infringement is pleaded and proven. |
| Siliconized inner surfaces in syringes/delivery devices |
Claims 17–19 |
Packaging-related claims may be infringed by container design choices; but proving device-level infringement is often evidentiary-heavy. |
How does the patent relate to “unpegylated interferon beta‑1a” products and what is the competitive relevance?
The patent’s commercial relevance is that it targets a formulation and delivery presentation for unpegylated interferon beta‑1a, not the pegylated molecule (which would have different structural claims in most estates). The claims do not protect the active ingredient generically. They protect a specific lyophilized formulation architecture: trehalose-based stabilization with a non-ionic surfactant and specified moisture/pH performance.
For business planning, this means:
- Generic entry risk is primarily formulation-centric. If a competitor can file a product that uses a different stabilizer system or misses one or more required components/ranges (especially trehalose dihydrate amount/range and surfactant class and concentration), it may design around claim 1 and fall outside dependent claims.
- If competitors use trehalose and polysorbate/PEG and hit similar concentration/moisture/pH windows, the patent estate becomes harder to avoid.
What patents likely cover around this formulation, and how many “layers” of IP usually overlap?
Without the full patent bibliographic record (filing date, assignees, cited references, and family members), a deterministic count of overlapping patents cannot be produced from the claim text alone. What can be analyzed from the claim architecture is the typical clustering of surrounding IP in this area:
Likely adjacent patent categories (typical in interferon lyophilized formulations)
-
Lyophilized formulation stabilization patents
- Trehalose and disaccharide bulking agents for protein stabilization in lyophilized interferons.
- Non-ionic surfactant selection (polysorbate/PEG) to prevent interfacial stress.
- Defined moisture limits and reconstitution pH windows.
-
Buffer system and antioxidant patents
- Phosphate/citrate buffer systems.
- Methionine as antioxidant for oxidation control.
-
Device and container-closure system patents
- Siliconization of prefilled syringes and inner-surface treatments to reduce adsorption and improve dosing.
- Claims to delivery devices and aqueous compositions in containers.
-
Method-of-use / indication patents
- Interferon beta‑1a in ARDS/SIRS and ischemia-reperfusion injury contexts.
- These claims often overlap with separate clinical and regulatory exclusivities and may drive Paragraph IV strategy.
For infringement strategy, the most dangerous “stack” is when a competitor’s ANDA product matches the formulation and also targets the same indication using the claimed lyophilized or reconstituted form.
When does US 10,293,030 lose exclusivity, and what are the generic-entry timing risks?
A complete exclusivity timeline cannot be calculated from the claim text alone because it depends on:
- patent issue date and filing date (for 20-year term),
- any patent term adjustment (PTA),
- any terminal disclaimers,
- and whether the asserted exclusivity is tied to patent term versus regulatory exclusivities.
Because you requested a comprehensive analysis, including expiration and Paragraph IV timing, the lack of the bibliographic data prevents a complete and accurate timeline from being produced.
What is the Orange Book status of interferon beta‑1a products likely relevant to US 10,293,030?
Orange Book status cannot be derived from the claim text. Orange Book listing requires the NDA/BLA number(s), listed drug products, and the associated patent numbers and expiration dates.
Because a correct Orange Book mapping is central to determining litigation and Paragraph IV pathways, this section cannot be completed accurately without the listed drug and the Orange Book patent-to-claim linkage.
How strong is the claim set for validity and infringement in US litigation?
Infringement: a map to measurable product attributes
The strongest infringement anchors are those with objective, assayable criteria:
- Trehalose dihydrate presence and mass per dose (30–50 mg).
- Surfactant class and concentration (polysorbate/PEG, and in claim 12: 0.05–0.15% w/v in aqueous precursor ranges).
- Potency threshold: biological activity >150 MIU/mg.
- Residual moisture ≤5% by weight.
- Reconstituted pH window: about 5.5–7.5.
- Methionine presence (for dependent claims).
The most contestable infringement issues usually arise from:
- Whether the accused product is exactly “unpegylated interferon beta‑1a.”
- Whether the claimed potency threshold is met under the relevant assay method.
- Whether the product uses trehalose dihydrate as specified (versus another disaccharide like sucrose, mannitol, or combinations not meeting the trehalose dihydrate requirement).
- Whether the surfactant is truly within the claimed class and concentration.
- Whether the accused buffer system and antioxidants align with the specific dependent claims.
Validity: obviousness vulnerabilities in formulation claims
Formulation patents face standard obviousness pressure when the combination of stabilization components is routine. From the claim text, the disclosed components are all common in lyophilized protein formulations:
- trehalose (or trehalose with sucrose),
- non-ionic surfactants (polysorbates/PEGs),
- phosphate/citrate buffers,
- methionine as antioxidant,
- moisture and pH windows.
The legal and technical leverage typically turns on:
- whether the patent credibly ties the specific ranges and conditions to an unexpected stability/ potency retention advantage,
- whether there is prior art showing the same exact combination with overlapping ranges,
- whether the potency threshold definition is supported as a functional property and how it would have been recognized as critical.
Likely defense arguments
Even without reviewing file history, common defenses consistent with this claim style include:
- Lack of enablement or indefiniteness around potency threshold measurement (“biological activity” and “MIU/mg” assay methodology).
- Obviousness based on known lyophilized interferon beta‑1a stabilizing formulations.
- Non-infringement due to different disaccharides, different surfactant types or concentrations, or buffer systems outside claim 5.
How do device claims (siliconized syringes) change the infringement risk profile?
Claims 16–19 extend coverage beyond the formulation to packaging: delivery device with an inner surface that is siliconized; and a prefilled syringe with siliconized inner surface.
This matters because a competitor might attempt to avoid formulation claims by using a different composition but still uses standard siliconized syringe technology; those device claims could still be asserted if the aqueous composition is also within claim 14/15.
Practically, device claims often increase settlement leverage but are not always the primary route of non-infringement, because changing container siliconization at scale can be commercially disruptive.
How do the indication claims affect enforcement strategy?
Method claims 20–23 focus on:
- ARDS vascular leakage/SIRS,
- ischemia-reperfusion injury in vascular/cardiac surgery and transplant,
- ischemic pre-conditioning prior to major surgery and transplant,
- multi-organ failure (MOF),
- IV administration.
For enforcement:
- If an accused product is approved for a different indication, proof of method-of-use infringement still requires mapping of prescribing and administration to the claimed method and patient population.
- If the competitor sells the same formulation but the clinical use is outside the claim indications, method claims become harder to enforce as a standalone route.
These method claims often become leverage points where product labeling or off-label promotion aligns with the claimed indications.
Key Takeaways
- US 10,293,030 is a formulation-focused estate: lyophilized unpegylated recombinant interferon beta‑1a with trehalose dihydrate (± sucrose), polysorbate/PEG surfactant, and hard performance constraints (reconstitution pH window and residual moisture cap), plus downstream claims to the reconstituted IV composition and siliconized delivery devices.
- The most infringement-sensitive variables are trehalose dihydrate identity and mass per single dose, interferon β‑1a potency threshold (>150 MIU/mg), surfactant class and concentration ranges, and residual moisture ≤5 wt%.
- Design-around efforts would most plausibly focus on: substituting the bulking agent system (not using trehalose dihydrate in the claimed range), using a buffer system outside the claimed phosphate/citrate species, changing surfactant class or concentration, or meeting but then disputing potency/moisture/pH mappings.
- Device and method-of-use claims expand enforcement pathways. Siliconized syringe/container choices can preserve device-level infringement risk even if some formulation elements are adjusted. Indication coverage determines how enforceable method claims are in real-world prescribing.
FAQs
1) What ingredients in US 10,293,030 are required for claim 1 infringement?
Lyophilized unpegylated recombinant interferon beta‑1a, trehalose dihydrate (or trehalose dihydrate plus sucrose) in 30–50 mg per single dose, and a non-ionic surfactant selected from polysorbate or polyethylene glycol, plus meeting the potency threshold >150 MIU/mg.
2) Does US 10,293,030 require methionine in the independent claim?
No. Methionine is required only in dependent claims (claims 6–7 and claim 11).
3) What product attributes are most measurable for enforcing or contesting this patent?
Residual moisture (≤5 wt%), reconstitution pH (about 5.5–7.5), disaccharide composition/amount (trehalose dihydrate ± sucrose), surfactant class and concentration (polysorbate/PEG), and potency (>150 MIU/mg).
4) Are the method-of-use claims limited to IV administration?
Claims 20 and 22/23 explicitly include IV administration (claim 21 and claim 23 narrow further to IV for those methods).
5) Do the device claims require that the formulation be in a prefilled syringe?
Not for the broad device claim: claim 16 covers a delivery device; claim 18 narrows to a prefilled syringe; claims 17 and 19 specify siliconized inner surfaces.
References (APA)
- US Patent 10,293,030.
